GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

Legislative efforts and a Trump administration initiative could lead in the near future to Medicare beneficiary access to ...

Relief is coming for more than 5 million Medicare beneficiaries who rely on expensive prescription medications.

Novo Nordisk, the Danish maker of the wildly popular Ozempic and Wegovy drugs used for weight loss, was downgraded due to ...

The Center for Medicare and Medicaid Innovation may introduce a five-year pilot model to expand access to weight loss drugs, ...